Skip to content
Biodatica
Start free

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Milan

OncologyGrant-only
Compare Sign in to watch

What changed

Study registered, no phase assigned: RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study

Jun 2025Trial registeredJun 22, 2025Source filing (opens the source filing in a new tab)

Momentum

44no change

Momentum 44 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

9,588 pre-ticker oncology companies at Grant-only

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    Study registered

    Feb 1, 2024

    Radiomic, Radiomics, Breast Cancer Metastatic, Breast Cancer Stage IV, Breast Carcinoma, Breast Neoplasms, Breast Cancer, Breast Cancer With Bone Metastasis, Breast Cancer With Metastatic Bone Disease, Trastuzumab, HER2, HER2 + Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Breast Cancer, Her2/Neu Positive Advanced Solid Tumors, HER2/Neu-positive Breast Cancer · RECRUITING · sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study

    ClinicalTrials.gov · NCT07030569 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources